RTI-229

In this article, we will analyze the impact of RTI-229 on contemporary society. Since its inception, RTI-229 has played a crucial role in various aspects of daily life, influencing everything from people's individual decisions to the future of events at a global level. Through in-depth analysis, we will examine the multiple angles from which RTI-229 has shaped our culture, our way of relating, and our perception of the world around us. Likewise, we will explore the ways in which RTI-229 continues to generate transformations, debating the ethical and moral implications it raises in today's society. Therefore, this article aims to offer a critical and reflective look at the impact of RTI-229 in the contemporary world.

RTI-229
Legal status
Legal status
  • In general: legal
Identifiers
  • octan-2-yl]-pyrrolidin-1-ylmethanone
CAS Number
PubChem CID
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H25IN2O
Molar mass424.326 g·mol−1
3D model (JSmol)
  • CN12CC1((C2)C3=CC=C(C=C3)I)C(=O)N4CCCC4
  (verify)

RTI-229, also known as (–)-3β-(4-iodophenyl)tropane-2β-pyrrolidine carboxamide and RTI-4229-229, is a potent and long-lasting stimulant drug which was developed in the 1990s as part of a large group of related analogues from the phenyltropane family. With the combination of two potent dopamine transporter (DAT) binding motifs attached to the tropane ring, the p-iodophenyl group at the 3β-position and a pyrrolidine carboxamide at 2β, RTI-229 has extremely high selectivity for the dopamine transporter (2600x and 4600x selective over NET and 5-HTT respectively) and is one of the most DAT-selective compounds in the RTI series.

Uses

RTI-229 is mainly used in scientific research into the dopamine reuptake transporter, with its extremely high DAT selectivity making it useful for distinguishing between DAT and NET binding sites in the brain to an even greater extent than related compounds such as RTI-121.

Legal Status

RTI-229 is legal throughout the world as of 2010. Some jurisdictions such as the United States, Australia and New Zealand might however consider RTI-229 to be a controlled substance analogue of cocaine on the grounds of its related chemical structure.

See also

References

  1. ^ Carroll FI, Kotian P, Dehghani A, Gray JL, Kuzemko MA, Parham KA, et al. (January 1995). "Cocaine and 3 beta-(4'-substituted phenyl)tropane-2 beta-carboxylic acid ester and amide analogues. New high-affinity and selective compounds for the dopamine transporter". Journal of Medicinal Chemistry. 38 (2): 379–88. doi:10.1021/jm00002a020. PMID 7830281.
  2. ^ Singh S (March 2000). "Chemistry, design, and structure-activity relationship of cocaine antagonists". Chemical Reviews. 100 (3): 925–1024. doi:10.1021/cr9700538. PMID 11749256.
  3. ^ Zhong D, Kotian P, Wyrick CD, Seltzman HH, Kepler JA, Kuhar MJ, Boja JW, Carroll FI (March 1999). "Synthesis of 3β-(4-iodophenyl)tropane-2β-pyrrolidine carboxamide (RTI-229)". Journal of Labelled Compounds and Radiopharmaceuticals. 42 (3): 281–286. doi:10.1002/(sici)1099-1344(199903)42:3<281::aid-jlcr188>3.3.co;2-o.

External links